Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mergers & Acquisitions
Pharma services firm Sygnature acquires DMPK specialist XenoGesis
by Michael McCoy
October 2, 2020
| A version of this story appeared in
Volume 98, Issue 38
The British contract research firm Sygnature has acquired XenoGesis, which it calls the UK’s largest independent company specializing in drug metabolism and pharmacokinetics. Both firms are based in the BioCity complex in Nottingham, England. Sygnature says the deal continues a push beyond its roots in pharmaceutical chemistry services. In recent years it has purchased the in vivo pharmacology providers RenaSci and Alderley Oncology.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X